Skip to content

A Pilot Functional Performances Study of Two Synthetic Male Condom

A Pilot Functional Performances Study of The Wondaleaf-Cap and The Wondaleaf-On-Man Synthetic Male Condom

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03324594
Acronym
WONDALEAF-MEN
Enrollment
50
Registered
2017-10-27
Start date
2017-11-01
Completion date
2018-03-31
Last updated
2018-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Performance, Synthetic Male Condom

Keywords

functional performance, synthetic male condom

Brief summary

Over the decades, male condoms had been widely commercialized and used to protect against unintended pregnancy and sexually transmitted infections (STI). While natural rubber latex (NRL) male condoms has majority proportion of male condoms in the market, synthetic male condoms (SMC) made from polyurethane or other synthetic materials remain new to the consumers. Notably, synthetic male condoms are found to be more durable, non-allergenic and have better compatibility with lubricants when compared to NRL male condoms. The SMCs that have FDA approval and commercially available are AvantiTM (polyisoprene condom), Trojan SupraTM (polyurethane condom) and eZ.onTM (polyurethane condom). Although the effectiveness of SMCs in the prevention of sexually transmitted infections has yet to be established, SMCs are believed to be comparable to NRL male condoms in both STI prevention and contraception protection. Notwithstanding, a recent literature had reported the shortfall on the quality of variant male condoms in the market, especially nonconforming volumetric capacity, burst pressure and freedom from holes. This warrant the current investigation, to evaluate the functional performances of two newly invented synthetic male condoms, branded as WONDALEAF-CAP (WLC) and WONDALEAF-ON-MAN (WLM). Apart from being made of polyurethane, the major feature of WLC and WLM are nonetheless their adhesive coating on the outer rim of the condom opening which by securely adhering to the foreskin, prevent slippage of condom and spillage of male ejaculate or secretions when the penis is flaccid, and thereby improve the user-friendliness of condom usage.

Interventions

DEVICE(1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator)

1. WONDALEAF-ON-MEN (WLM) is a polyurethane pouch with outstretching adhesive shield. The pouch covers the penis in man user; while the adhesive shield covers the groin regions to provide extra protection for the couples. The pouch is equivalent to marketed polyurethane male; while the adhesive shield is equivalent to marketed polyurethane wound dressing. WLM integrally joined with an adhesive wound dressing, both made of the same polyurethane material. 2. WONDALEAF-CAP (WLC) is a miniature form of WLM: the pouch covers glans penis and the adhesive shield wraps around the shaft of the penis only, thereby emulating the configuration of a donned regular condom on the penis. Because of the adhesive coating, WLC overcomes the problems of slippage when the penis is flaccid. 3. The durex-TOGETHER serves as the active comparator in this study. It is a transparent natural rubber latex male condom which is commercially available.

Sponsors

Twin Catalyst Sdn. Bhd.
CollaboratorINDUSTRY
Sarawak Research Society
CollaboratorUNKNOWN
Clinical Research Centre, Malaysia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DEVICE_FEASIBILITY
Masking
SINGLE (Outcomes Assessor)

Masking description

Throughout the study, neither participating couples, clinic staff, research assistants or researchers are masked to condom assignment as there are observable differences on packaging and design between the test condom (WLC and WLM) and the control condom (durex-Together). However, statisticians, sponsors, and medical reviewers are masked until completion of the final report to minimize biases potentially emerge during data analyses and results reporting.

Eligibility

Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

1. Their female sexual partners are not at risk of pregnancy (using alternate contraception); 2. They don't have known sexually transmitted infections, including HIV/AIDS; 3. They should be experienced condom users, minimum 10 male condoms used in the last 12 months; 4. They are between 18 to 45 years of age; 5. They are in a monogamous heterosexual relationship and agree to practice vaginal sex only using male condoms provided by the study.

Exclusion criteria

1. couples who work for the research team or who are close relatives of the research team; 2. men with known allergy to natural rubber latex; 3. men with known sensitivity to the residual chemicals used in the manufacture of natural rubber latex condoms or the test condom materials; 4. couples where one knowingly has a sexually transmitted infection. 5. couples who are pregnant in time of recruitment

Design outcomes

Primary

MeasureTime frameDescription
Clinical Slippage Rates (CSR)Through study completion, an average of 3 months. In specific, CSR will be evaluated within 24 hours after use of individual condom, for each condom typeNumber of condoms that slipped completely off the penis during intercourse or withdrawal, divided by the number of condoms used during intercourse; reported as a percentage.
Clinical Breakage Rates (CBR)Through study completion, an average of 3 months. In specific, CBR will be evaluated within 24 hours after use of individual condom, for each condom typeNumber of condoms that broke during intercourse or withdrawal, divided by the number of condoms used during intercourse; reported as a percentage.
Clinical Failure Rates (CFR)Through study completion, an average of 3 months. In specific, CFR will be calculated after completion of four times usage, for each condom typeCFR is the sum of CSR and CBR for each condom type

Secondary

MeasureTime frameDescription
Favorability of product attributesThrough study completion, an average of 3 months. In specific, it will be measured after completion of four times usage, for each condom typeThis will reflect the acceptability of the male condoms used. It is a self-reported favorability towards attributes of each male condoms' type used
Incidence of Treatment-Emergent Adverse EventsThrough study completion, an average of 3 months. In specific, it will be measured after completion of four times usage, for each condom typeThis outcome will reflect the safety of the male condoms used. Proportion of participants with symptoms of and proportion of condom uses with reports of individual complaints (eg. irritation, burning, itching, bleeding, etc.) during or immediately after any of the 3 separate uses will be calculated for each condom type. Adverse events will be classified by relatedness, expectedness and severity.
Adequacy and feel of lubricationThrough study completion, an average of 3 months. In specific, it will be measured after completion of four times usage, for each condom typeThis will reflect the acceptability of the male condoms used. It is a self-reported adequacy and feel of lubrication for each type of male condoms used.
Comfort in useThrough study completion, an average of 3 months. In specific, it will be measured after completion of four times usage, for each condom typeThis will reflect the acceptability of the male condoms used. It is a self-reported comfortability on each type of male condoms used
Ease of insertion and removalThrough study completion, an average of 3 months. In specific, it will be measured after completion of four times usage, for each condom typeThis will reflect the acceptability of the male condoms used. It is a self-reported ease of insertion and removal for each type of male condoms used

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026